Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk | live
By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk. The trillion-dollar company also posted better-than-expected quarterly results and raised its full-year revenue forecast, and its shares were up 2.5%.
By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk. The trillion-dollar company also posted better-than-expected quarterly results and raised its full-year revenue forecast, and its shares were up 2.5%.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
